Pasadena, California, USA, November 13, 2026
Ventric Health and Stellus Rx have announced a strategic collaboration aimed at improving the early detection and treatment of heart failure by connecting point-of-care diagnostic technology with specialised clinical pharmacy services. The partnership is designed to address a major challenge in cardiovascular healthcare: ensuring that patients identified with early-stage heart failure receive timely and appropriately optimised treatment. Through the collaboration, Ventric Health’s FDA-cleared Vivio® System will be integrated into a care pathway supported by Stellus Rx’s pharmacist-led medication management services. The approach combines non-invasive cardiovascular assessment with ongoing clinical monitoring, medication adjustments and patient support. Vivio can identify elevated left ventricular end-diastolic pressure (LVEDP) in less than five minutes during a standard primary care visit, helping clinicians recognise potential heart failure earlier. Following identification, eligible patients can be connected with Stellus Rx’s virtual clinical pharmacy team to support the initiation and optimisation of Guideline-Directed Medical Therapy (GDMT). The collaboration aims to improve treatment adherence, reduce delays in medication optimisation and support better long-term cardiovascular care. It also highlights the growing role of integrated medical technology and clinical pharmacy services in managing chronic cardiovascular conditions.
Vivio System Supports Early Heart Failure Detection
One of the key components of the collaboration is the Vivio® System, a non-invasive diagnostic technology developed by Ventric Health to identify elevated LVEDP, an important physiological indicator associated with heart failure. The system uses an advanced analysis of cardiac pressure and volume waveforms to assess cardiovascular function without requiring invasive procedures or conventional cardiac imaging. The test can be performed in a primary care setting in under five minutes, providing clinicians with actionable information during routine patient visits. It also incorporates the digital Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which helps assess patients’ symptoms and the impact of heart failure on their quality of life. The technology is designed to help identify individuals with Stage B and Stage C heart failure, including patients who may not yet have developed obvious symptoms. Early identification is particularly important among individuals with risk factors such as hypertension, type 2 diabetes and chronic kidney disease, who may have an increased likelihood of developing cardiovascular complications. By bringing non-invasive heart failure assessment into primary care practices, Ventric Health aims to support earlier clinical evaluation and timely treatment decisions.
Stellus Rx Pharmacists Support Four-Pillar GDMT
Following early heart failure identification, Stellus Rx will provide specialised virtual pharmacy care management to support patients and primary care providers in optimising medication treatment. The programme focuses on the four major pillars of guideline-directed medical therapy for heart failure: angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors. These medication classes play important roles in reducing cardiovascular complications and improving outcomes in eligible patients with heart failure. However, achieving recommended therapeutic doses can require frequent clinical assessments, laboratory monitoring, medication adjustments and patient education. Stellus Rx’s clinical pharmacists will conduct biweekly patient follow-ups, monitor vital signs, review laboratory results and support medication titration in coordination with prescribing physicians. The pharmacists can also assist with prior authorisation requirements, medication affordability challenges and treatment adherence. Patients may receive medications through home delivery, with customised compliance packaging available when appropriate. The clinical pharmacy team will also be integrated into participating practices’ electronic health record (EHR) systems, enabling communication between pharmacists and primary care providers regarding patient progress, treatment adjustments and monitoring requirements.
Collaboration Targets Better Cardiovascular Care Outcomes
The partnership is intended to establish a more coordinated approach to heart failure management by connecting early diagnosis with ongoing medication optimisation. For healthcare providers, the model could help reduce administrative and clinical workloads associated with complex medication regimens, frequent dose adjustments and laboratory monitoring. It is also designed to support health systems, Medicare Accountable Care Organizations (ACOs) and Medicare Advantage plans seeking to improve cardiovascular outcomes while managing healthcare expenditure. According to the companies, comprehensive four-pillar GDMT can provide substantial long-term benefits for eligible patients, including reductions in cardiovascular death and heart failure hospitalisation. Research published in The Lancet has estimated that comprehensive disease-modifying pharmacological treatment could provide more than eight additional years free from cardiovascular death or heart failure hospitalisation for a 55-year-old patient with heart failure with reduced ejection fraction, compared with conventional dual therapy. The collaboration seeks to translate the benefits of guideline-directed treatment into more accessible primary care workflows. By combining rapid non-invasive diagnostics, pharmacist-led medication management and EHR-integrated clinical monitoring, Ventric Health and Stellus Rx aim to strengthen the transition from early heart failure detection to sustained treatment optimisation. The companies expect the integrated model to support improved patient management, medication adherence and potentially fewer avoidable hospital visits. However, the collaboration’s impact on hospitalisation rates and long-term clinical outcomes will need to be established through real-world implementation and outcome evaluation.
Source: Ventric Health, Stellus Rx press release


